Delayed
Other stock markets
|
5-day change | 1st Jan Change | ||
- EUR | -.--% |
|
-.--% | -.--% |
06-28 | Protagonist Therapeutics to Join S&P SmallCap 600 | MT |
06-27 | Persson sells Prysmian shares for more than EUR30,000 | AN |
Sales 2024 * | 15.59B 16.7B 22.83B | Sales 2025 * | 16.47B 17.64B 24.12B | Capitalization | 15.79B 16.91B 23.12B |
---|---|---|---|---|---|
Net income 2024 * | 805M 862M 1.18B | Net income 2025 * | 864M 925M 1.27B | EV / Sales 2024 * | 1.05 x |
Net Debt 2024 * | 571M 612M 837M | Net Debt 2025 * | 328M 351M 480M | EV / Sales 2025 * | 0.98 x |
P/E ratio 2024 * |
19.7
x | P/E ratio 2025 * |
18.3
x | Employees | - |
Yield 2024 * |
1.33% | Yield 2025 * |
1.5% | Free-Float | 98.66% |
Latest transcript on Prysmian
Managers | Title | Age | Since |
---|---|---|---|
Massimo Battaini
CEO | Chief Executive Officer | 62 | 10-12-31 |
Director of Finance/CFO | 55 | 07-01-31 | |
Chief Tech/Sci/R&D Officer | 48 | 18-05-31 |
Members of the board | Title | Age | Since |
---|---|---|---|
Valerio Battista
BRD | Director/Board Member | 67 | 05-11-30 |
Francesco Gori
CHM | Chairman | 72 | 18-09-17 |
Director of Finance/CFO | 55 | 07-01-31 |
![Consensus](/images/consensus_flch.gif)
EPS Revisions
1st Jan change | Capi. | |
---|---|---|
+29.84% | 4.81B | |
+35.97% | 4.79B | |
+14.18% | 4.62B | |
+35.69% | 4.58B | |
-8.15% | 4.41B | |
+8.86% | 4.02B | |
+54.40% | 2.86B | |
+64.29% | 2.23B | |
-17.75% | 1.51B |
- Stock Market
- Equities
- PRY Stock
- PRY Stock